Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL5936052 | 1.00 | MCHR1 (0.86) | MCHR1KCNH2 | |
| SCHEMBL5936025 | 0.93 | MCHR1 (0.98) | MCHR1KCNH2 | |
| SCHEMBL5936098 | 0.93 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL5766737 | 0.86 | MCHR1 (0.81) | MCHR1KCNH2 | |
| SCHEMBL5936020 | 0.83 | MCHR1 (0.77) | MCHR1KCNH2 | |
| SCHEMBL6231476 | 0.82 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5936028 | 0.81 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL6237332 | 0.81 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL5936181 | 0.79 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL5936172 | 0.79 | MCHR1 (0.71) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194871-A1 | Heterocyclic mchr1 antagoists | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| WO-2004092181-A9 | HETEROCYCLIC MCHR1 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194871-A1 | Heterocyclic mchr1 antagoists | MCHR1, MCHR2, MC1R | KCNH2 4037/4885MCHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.